Blog
RSS FeedPosted by Michael Wonder on 19 Aug 2021
CADTH welcomes transfer of drug safety and effectiveness network
13 August 2021 - CADTH welcomes today’s announcement by the Canadian Institutes of Health Research and Health Canada that they ...
Posted by Michael Wonder on 19 Aug 2021
NICE’s health technology assessment methods and processes to be evaluated
19 August 2021 - NICE has launched a public consultation on proposed changes to the way it develops recommendations across ...
Posted by Michael Wonder on 19 Aug 2021
EMA validates Gilead’s marketing authorisation application for lenacapavir, an investigational, long-acting capsid inhibitor for the treatment of HIV-1 in people with limited therapy options
19 August 2021 - EMA MAA validation follows submission of NDA for Lenacapavir to the U.S. FDA. ...
Posted by Michael Wonder on 19 Aug 2021
Senhwa's silmitasertib receives US FDA fast track designation for the treatment of recurrent sonic hedgehog driven medulloblastoma
19 August 2021 - Senhwa Biosciences today announced that the US FDA has granted fast track designation for silmitasertib, a highly ...
Posted by Michael Wonder on 19 Aug 2021
NICE recommends first treatment for rare blood disorder
19 August 2021 - People with a rare blood disorder have access to a new treatment following draft guidance from NICE. ...
Posted by Michael Wonder on 19 Aug 2021
BeiGene announces acceptance by Swissmedic of marketing authorisation application for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
18 August 2021 - BeiGene announced that Swissmedic has accepted the marketing authorisation application for Brukinsa, a treatment option for adult ...
Posted by Michael Wonder on 19 Aug 2021
Miravo Healthcare announces receipt of Health Canada Notice of Compliance for the paediatric use of Blexten
12 August 2021 - Blexten Label Expanded to Include Ages as Young as 4 Years Old. ...
Posted by Michael Wonder on 19 Aug 2021
TGA reduces timeframe for publishing adverse event reports
19 August 2021 - With strong public interest in adverse event reports relating to COVID-19 vaccinations, and improvements in our ...
Posted by Michael Wonder on 18 Aug 2021
NICE publishes final guidance on the use of a topical gel for patients with a rare cancer
18 August 2021 - Chlormethine gel for is used for the treatment of patients with mycosis fungoides type cutaneous T-cell lymphoma. ...
Posted by Michael Wonder on 18 Aug 2021
MS drug: Hull couple's treatment denied by 'cruel' postcode lottery
18 August 2021 - A couple who both have multiple sclerosis say they are being denied a drug which could ...
Posted by Michael Wonder on 18 Aug 2021
WHO calls on Roche to ensure fair access to COVID-19 drug amid shortage
18 August 2021 - The World Health Organization called on Wednesday on Roche to ensure fair distribution of its arthritis ...
Posted by Michael Wonder on 18 Aug 2021
ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 18 Aug 2021
US FDA approves Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
18 August 2021 - New treatment options are critical, as approximately half of all people with heart failure die within five ...
Posted by Michael Wonder on 18 Aug 2021
Talks to recover reimbursement for dementia treatment aid almost complete
18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...
Posted by Michael Wonder on 18 Aug 2021
Sutro Biopharma announces STRO-002 FDA fast track designation for patients with advanced ovarian cancer
18 August 2021 - Sutro Biopharma today announced that the U.S. FDA has granted fast track designation for STRO-002, a folate ...